1. Home
  2. LYEL

as 09-12-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Founded: 2018 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 207.7M IPO Year: 2021
Target Price: $15.00 AVG Volume (30 days): 24.3K
Analyst Decision: Sell Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -23.52 EPS Growth: N/A
52 Week Low/High: $7.65 - $32.00 Next Earning Date: 11-06-2025
Revenue: $60,000 Revenue Growth: 11.11%
Revenue Growth (this year): -82.16% Revenue Growth (next year): N/A

LYEL Daily Stock ML Predictions

Stock Insider Trading Activity of Lyell Immunopharma Inc. (LYEL)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Hill Stephen J. LYEL Chief Operating Officer Aug 21 '25 Sell $10.54 1,004 $10,586.18 15,845
Seely Lynn LYEL President and CEO Aug 21 '25 Sell $10.54 7,257 $76,517.81 67,571
Lee Gary K. LYEL Chief Scientific Officer Aug 21 '25 Sell $10.54 1,453 $15,320.43 15,504
Newton Charles W. LYEL Chief Financial Officer Aug 21 '25 Sell $10.54 1,453 $15,320.43 15,306
Hill Stephen J. LYEL Chief Operating Officer Aug 12 '25 Sell $10.34 94 $971.77 15,845
Seely Lynn LYEL President and CEO Aug 12 '25 Sell $10.34 406 $4,197.23 67,571
Lee Gary K. LYEL Chief Scientific Officer Aug 12 '25 Sell $10.34 136 $1,405.97 15,504
Newton Charles W. LYEL Chief Financial Officer Aug 12 '25 Sell $10.34 136 $1,405.97 15,306
Hill Stephen J. LYEL Chief Operating Officer Aug 11 '25 Sell $10.53 91 $957.87 15,845
Seely Lynn LYEL President and CEO Aug 11 '25 Sell $10.53 391 $4,115.67 67,571

Share on Social Networks: